BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

Gilead’s second CAR T under Priority Review  Gilead Sciences Inc. (NASDAQ:GILD) said FDA accepted and granted Priority Review to a BLA for KTE-X19 to treat adults with relapse or refractory mantle cell lymphoma. The anti-CD19...
BC Extra | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody  Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
BC Innovations | Aug 1, 2019
Distillery Therapeutics

A pyrrolopyrimidine-based TYRO3 inhibitor for primary effusion lymphoma

DISEASE CATEGORY: Cancer INDICATION: Non-Hodgkin lymphoma (NHL) A UNC Chapel Hill team identified a pyrrolopyrimidine-based inhibitor of TYRO3 that could treat the primary effusion lymphoma (PEL), an NHL subtype. TYRO3 mRNA levels were higher in...
BC Extra | Jul 3, 2019
Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Week In Review | Feb 8, 2019
Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from...
BC Extra | Feb 7, 2019
Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Thursday from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers...
BC Week In Review | Oct 26, 2018
Clinical News

Mirati reports updated confirmed ORR of 16% in Phase II of sitravatinib for NSCLC

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus PD-1...
BC Extra | Oct 22, 2018
Clinical News

Mirati falls on updated response data for sitravatinib in NSCLC

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data Monday from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus...
Items per page:
1 - 10 of 119